GKWIM
UBX

Gerber Kawasaki Wealth & Investment Management’s Unity Biotechnology UBX Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20
Closed – – 1053
2021
Q3 		$0 Buy
+20
New +$706 ﹤0.01% 1232

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's UBX Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 20 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in UBX in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 20 Unity Biotechnology shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Unity Biotechnology in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Unity Biotechnology position peaked at $0 in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.